{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:03:08Z","timestamp":1790006588951,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00827-3","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:21:15Z","timestamp":1790004075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal Trends and Predictors of P2Y12 Inhibitor Selection and Switching Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3050-0252","authenticated-orcid":false,"given":"Young Eun","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Hincapie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"827_CR1","unstructured":"Singh A, Museedi AS, Grossman SA. Acute coronary syndrome. StatPearls. StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"8","key":"827_CR2","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/cir.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93\u2013621. https:\/\/doi.org\/10.1161\/cir.0000000000001123.","journal-title":"Circulation"},{"issue":"4","key":"827_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0885066613503294","volume":"30","author":"N Makki","year":"2015","unstructured":"Makki N, Brennan TM, Girotra S. Acute coronary syndrome. J Intensive Care Med. 2015;30(4):186\u2013200. https:\/\/doi.org\/10.1177\/0885066613503294.","journal-title":"J Intensive Care Med"},{"issue":"2 Suppl","key":"827_CR4","first-page":"S36","volume":"15","author":"DM Kolansky","year":"2009","unstructured":"Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15(2 Suppl):S36-41.","journal-title":"Am J Manag Care"},{"issue":"2","key":"827_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1185\/030079908x261096","volume":"24","author":"J Menzin","year":"2008","unstructured":"Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008;24(2):461\u20138. https:\/\/doi.org\/10.1185\/030079908x261096.","journal-title":"Curr Med Res Opin"},{"issue":"25","key":"827_CR6","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/cir.0000000000000134","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-426. https:\/\/doi.org\/10.1161\/cir.0000000000000134.","journal-title":"Circulation"},{"issue":"10","key":"827_CR7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"827_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O'Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529\u201355. https:\/\/doi.org\/10.1161\/CIR.0b013e3182742c84.","journal-title":"Circulation"},{"issue":"6","key":"827_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"R Mehran","year":"2011","unstructured":"Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv. 2011;4(6):654\u201364. https:\/\/doi.org\/10.1016\/j.jcin.2011.02.011.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"827_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","volume":"38","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehw525.","journal-title":"Eur Heart J"},{"issue":"21","key":"827_CR11","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"EM Antman","year":"2008","unstructured":"Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2008.04.002.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"827_CR12","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehr422.","journal-title":"Eur Heart J"},{"issue":"41","key":"827_CR13","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehx175.","journal-title":"Eur Heart J"},{"issue":"10104","key":"827_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/s0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(17)32155-4.","journal-title":"Lancet"},{"issue":"10308","key":"827_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/s0140-6736(21)01445-8","volume":"398","author":"CJ Kim","year":"2021","unstructured":"Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(21)01445-8.","journal-title":"Lancet"},{"issue":"44","key":"827_CR16","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","volume":"37","author":"A Sahl\u00e9n","year":"2016","unstructured":"Sahl\u00e9n A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37(44):3335\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehw284.","journal-title":"Eur Heart J"},{"issue":"4","key":"827_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4244\/eij-d-17-00092","volume":"13","author":"L De Luca","year":"2017","unstructured":"De Luca L, D\u2019Ascenzo F, Musumeci G, et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention. 2017;13(4):459\u201366. https:\/\/doi.org\/10.4244\/eij-d-17-00092.","journal-title":"EuroIntervention"},{"key":"827_CR18","first-page":"0209","volume":"2010","author":"ML Sarkees","year":"2010","unstructured":"Sarkees ML, Bavry AA. Non ST-elevation acute coronary syndrome. BMJ Clin Evid. 2010;2010:0209.","journal-title":"BMJ Clin Evid."},{"issue":"1","key":"827_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/cer.14.53","volume":"4","author":"AW Roberts","year":"2015","unstructured":"Roberts AW, Dusetzina SB, Farley JF. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. J Comp Eff Res. 2015;4(1):27\u201335. https:\/\/doi.org\/10.2217\/cer.14.53.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"827_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjh.15857","volume":"185","author":"PL Lutsey","year":"2019","unstructured":"Lutsey PL, Zakai NA, MacLehose RF, et al. Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism. Br J Haematol. 2019;185(5):903\u201311. https:\/\/doi.org\/10.1111\/bjh.15857.","journal-title":"Br J Haematol"},{"issue":"1","key":"827_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"RM Andersen","year":"1995","unstructured":"Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1\u201310.","journal-title":"J Health Soc Behav"},{"issue":"1","key":"827_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"issue":"6","key":"827_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","volume":"47","author":"C van Walraven","year":"2009","unstructured":"van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626\u201333. https:\/\/doi.org\/10.1097\/MLR.0b013e31819432e5.","journal-title":"Med Care"},{"issue":"10","key":"827_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00380-019-01405-1","volume":"34","author":"D Castini","year":"2019","unstructured":"Castini D, Persampieri S, Sabatelli L, et al. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels. 2019;34(10):1621\u201330. https:\/\/doi.org\/10.1007\/s00380-019-01405-1.","journal-title":"Heart Vessels"},{"issue":"2","key":"827_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ccd.28072","volume":"94","author":"J Potts","year":"2019","unstructured":"Potts J, Nagaraja V, Al Suwaidi J, et al. The influence of Elixhauser comorbidity index on percutaneous coronary intervention outcomes. Catheter Cardiovasc Interv. 2019;94(2):195\u2013203. https:\/\/doi.org\/10.1002\/ccd.28072.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"827_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/cpt.2806","volume":"113","author":"A Kumar","year":"2023","unstructured":"Kumar A, Lutsey PL, St Peter WL, et al. Comparative risk of hospitalized bleeding of P2Y12 inhibitors for secondary prophylaxis in acute coronary syndrome after percutaneous coronary intervention. Clin Pharmacol Ther. 2023;113(2):412\u201322. https:\/\/doi.org\/10.1002\/cpt.2806.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"827_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cpt.2797","volume":"113","author":"A Kumar","year":"2023","unstructured":"Kumar A, Lutsey PL, St Peter WL, et al. Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study. Clin Pharmacol Ther. 2023;113(2):401\u201311. https:\/\/doi.org\/10.1002\/cpt.2797.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"827_CR28","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/cts.13596","volume":"16","author":"A Kumar","year":"2013","unstructured":"Kumar A, Lutsey PL, St. Peter WL, et al. Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013\u20132018. Clin Transl Sci. 2013;16(10):1886\u201397. https:\/\/doi.org\/10.1111\/cts.13596.","journal-title":"Clin Transl Sci"},{"key":"827_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.amjcard.2023.03.012","volume":"198","author":"EJ Wiens","year":"2023","unstructured":"Wiens EJ, Leon SJ, Whitlock R, Tangri N, Shah AH. Ticagrelor as compared to clopidogrel following percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2023;198:26\u201332. https:\/\/doi.org\/10.1016\/j.amjcard.2023.03.012.","journal-title":"Am J Cardiol"},{"key":"827_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-001999","author":"M Pufulete","year":"2022","unstructured":"Pufulete M, Harris J, Pouwels K, et al. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a \u201ctarget trial.\u201d Open Heart. 2022. https:\/\/doi.org\/10.1136\/openhrt-2022-001999.","journal-title":"Open Heart"},{"issue":"4","key":"827_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.8585","volume":"6","author":"Y Wang","year":"2023","unstructured":"Wang Y, Cavallari LH, Brown JD, Thomas CD, Winterstein AG. Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US. JAMA Netw Open. 2023;6(4):e238585. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.8585.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"827_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/09537104.2019.1609668","volume":"31","author":"C Wang","year":"2020","unstructured":"Wang C, Zheng W, Shaqdan A, et al. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention. Platelets. 2020;31(3):337\u201343. https:\/\/doi.org\/10.1080\/09537104.2019.1609668.","journal-title":"Platelets"},{"issue":"21","key":"827_CR33","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1908419.","journal-title":"N Engl J Med"},{"issue":"10151","key":"827_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0.","journal-title":"Lancet"},{"issue":"11","key":"827_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00827-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:21:17Z","timestamp":1790004077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00827-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":35,"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00827-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Young Eun Shin is currently an employee of Boston Scientific Corporation, Marlborough, MA, USA; however, this employment began after the study was completed, and Boston Scientific Corporation had no role in the study design, data collection, analysis, interpretation of the results, or manuscript preparation. Arun Kumar is a current\u00a0employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, NJ, USA, and stockholder of Merck & Co., Inc., Rahway, NJ, USA. All other authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the University of Cincinnati Institutional Review Board. The study analyzed de-identified data; informed consent was waived.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are not publicly available because they were accessed through TriNetX under a licensed data use agreement held by the University of Cincinnati. Requests for access may be directed to the corresponding author and are subject to TriNetX approval and the terms of the relevant data use agreement.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by YES. The first draft of the manuscript was written by YES, and AK, AM, PW, JG, and ALH commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}